While its pharmacological properties have prompted investigation into systemic applications for various inflammatory and metabolic disorders, the systemic administration of PDE4 inhibitors, including agents such as AMX, is commonly associated with adverse effects such as nausea, vomiting, and gastrointestinal discomfort. The gene discussed is PDE4A; the disease is metabolic disease.